E-Cadherin is calcium-dependent cell adhesion molecule encoded by CDH1 gene at chromosome 16q22.1. Ecadherin regulates cell-cell adhesions and controls mobility and proliferation of epithelial cells. Recently, the role of E-cadherin in erythroid maturation has been elucidated. It is selectively expressed in immature erythroblasts and gradually down regulated as erythroid precursors mature. Acute erythroid leukemia is neoplastic proliferation of immature erythroid precursors in bone marrow with or without significant myeloblasts component. In the recent years E-cadherin has emerged as the most sensitive and specific marker for immature erythroblasts. Moreover, combination of E-cadherin with glycophorin A in immunohistochemistry staining can effectively separate immature vs. mature erythroid precursors in bone marrow biopsy. In this short review I will shed light on the key points related to the nature of relationship between E-cadherin and acute erythroid leukemia.
Introduction E-cadherin
E-cadherin (epithelial cadherin) is a polypeptide protein belongs to cadherins family whose primary function is to facilitate cell-cell adhesion and recognition [1] . Cadherins are class-1 transmembrane proteins named for "calcium-dependent adhesion" because they are dependent on calcium (Ca 2+ ) ions to function [2] . E-cadherin is encoded by CDH1 gene which is located on the long (q) arm of chromosome 16 at position 22.1. [3] It is mainly expressed on epithelial cells and behaves as both receptor and ligand for other molecules and can be used as a marker for epithelial differentiation owing to limited expression to the cells of epithelial origin. In addition to that, E-cadherin has a major role in the morphogenesis of cells during migration and acts as tumor suppressor gene [4, 5] . In some solid tumors, such as breast cancer, loss of E-cadherin function is often associated with tumor progression and transition to more invasive disease [6] .
Acute erythroid leukemia (AEL)
AEL is a unique type of acute myeloid leukemia characterized by proliferation of immature erythroid precursors (typically >50%) [7] . AEL is divided into two subtypes based on presence or absence of a significant myeloid component: Erythroleukemia and pure erythroid leukemia erythroleukemia (erythroid/myeloid) is characterized by marked erythroid proliferation (≥ 50% of the entire BM cells) accompanied with significant number of myeloblasts (≥ 20% of nonerythroid cells). Typically, the erythroid component is composed of all stage of maturation with shift to immaturity and significant dysplastic features such as megaloblastoid changes and multi nucleation. Pure erythroid leukemia is neoplastic proliferation of proerythroblasts (the early recognizable erythroid precursors) and other immature erythroid precursors comprising at least 80% of bone marrow cells. Myeloblasts are not detected in this subtype [7] [8] [9] .
Erythroblasts express erythrocyte associated antigens; this expression correlates with the degree of differentiation or maturation of the neoplastic cells. Erythroblasts usually express CD71 (transferrin receptor) hemoglobin A, glycophorin A, ABH blood group antigens, and HLA-DR. Occasionally, expression of CD71 and glycophorin A can be aberrantly dim or often negative especially in immature stages of erythropoiesis. Erythroid precursors are classically negative for myeloid associated antigens such as CD13, CD33, and MPO. Immature markers such as CD34 and TDT are usually negative as well [10] [11] [12] .
The emerging story
In 1995, Sorin A et al. proved that E-cadherin plays a major role in the maturation of the erythroid lineage [13] . This non anticipated finding was confirmed by western blot (WB) analysis and immunofluorescence staining of bone marrow samples. Dual color flow cytometry revealed that the expression of E-cadherin is restricted to immature erythroid precursor (pro-erythroblasts and basophilic erythroblasts) while more mature erythroid precursors are negative. Interestingly, Erythropoiesis was dramatically diminished when anti-E-cadherin antibody was added to bone marrow culture .It is postulated that E-cadherin has a major role in establishment of an appropriate microenvironment necessary for erythroid maturation [14] .
The subsequent studies highlighted the significance of this finding [15] [16] [17] . G Acs et al showed that E-cadherin was strongly expressed in normal erythroid precursors of normal bone marrow specimens. In contrast, erythroblasts in erthroleukemia (erythroid/myeloid leukemia) lack membrane E-cadherin expression. However, the majority of erythroleukemia cases expressed E-cadherin as a Golgi distribution pattern, but not as cell surface pattern. Additionally, Ecadherin expression was stronger in more immature erythroid precursors and down regulated during erythroid maturation [18] .
In the research of Liu et al., E-cadherin showed weak-to strong membrane reactivity in sheets of large, immature erythroblasts in 13 of 14 cases (93%) of pure erythroid leukemia, while Glycophorin A stained mainly the mature erythroblasts but was weakly positive in the immature erythroblasts (21%). The combination of E-cadherin with glycophorin effectively separated immature vs. mature erythroid precursors in bone marrow biopsy section. Moreover, the variability in the staining pattern (Golgi vs. membranous) is demonstrated in normal and abnormal erythroid precursors [19] . This variability makes a distinction between immature and mature erythroid precursors based on E-cadherin expression alone is a bet difficult. In a unique study, Robert et al. examined 84 cases, including almost all acute myeloid leukemia subtypes, in order to determine the specificity of E-cadherin for leukemic blasts [14] . Of these 84 cases, six showed significant positivity (>50%) for E-cadherin; 5 cases of acute erythroid leukemia and one megakaryoblastic leukemia associated with Down syndrome which was positive as well. Of the five cases of acute erythroid leukemia, one case was pure erythroid leukemia (PEL) and the rest were acute erythroid myeloid leukemia cases. The only case which was positive for E-cadherin and did not belong to acute erythroid leukemia expressed other markers of erythroid differentiation such as glycophorin A. This case is likely to have proliferation of both malignant erythroblasts and megakaryoblasts however; no certain conclusion can be obtained.
Our local experience with E-cadherin is in agreement with the published literature. We received 2 cases of pure erythroid leukemia in the last 3 years. The first case was for middle age patient who diagnosed with pure erythroid leukemia after long history of alcohol abuse [20] . Immunohistochemistry for this case showed strong positivity (≈ 80%) to E-cadherin (ECH-6; Ventana Medical Systems, Inc., Roche, Basel, Switzerland), weak positivity (≈ 20%) for glycophorin A (GA-R2; Ventana Medical Systems, Inc.) and negative for CD34, MPO, vWF, CD3 and CD79a. In fact, the combination of Ecadherin with glycophorin A distinguished between immature and mature erythroid precursors efficiently (Figure1).
The second case was for 21 year old patient who presented with poorly differentiated blasts in peripheral blood and bone marrow. The infiltrating blasts were completely negative for Glycophorin A and all other myeloid and lymphoid markers including CD41 and CD61. CD36 and CD71 were partially positive. Interestingly, E-cadherin was strongly expressed by almost all immature cells (≈ 95%) and was quite helpful in pure erythroid leukemia diagnosis. This patient underwent allogeneic stem cell transplantation but unfortunately, he relapsed after 6 months with circulating erythroblasts and moderate bone marrow fibrosis. E-cadherin was moderately positive (≈ 40%) in immature erythroid precursors. E-cadherin stain is a useful marker that more clearly defines immature erythroid cells compared to glycophorin A [17] .
Conclusion
The utility of E-cadherin stain as specific and sensitive marker for erythroid differentiation has been elucidated in reasonable number of cases. Moreover, it is useful marker that distinguishes pure erythroid leukemia from other erythroid proliferation. Molecular studies, preferably using high-throughput methods, are needed to clarify the nature of the relationship between abnormal expression of E-cadherin and tumorigenesis in acute erythroid leukemia.
